BR9916576A - Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 - Google Patents
Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2Info
- Publication number
- BR9916576A BR9916576A BR9916576-7A BR9916576A BR9916576A BR 9916576 A BR9916576 A BR 9916576A BR 9916576 A BR9916576 A BR 9916576A BR 9916576 A BR9916576 A BR 9916576A
- Authority
- BR
- Brazil
- Prior art keywords
- receptors
- increase
- treatment
- diseases associated
- receptor
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 229940075993 receptor modulator Drugs 0.000 title abstract 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Patente de Invenção:<B>"USO DE ANTAGONISTA RECEPTOR AT-1 OU MODULADOR RECEPTOR AT-2 PARA O TRATAMENTO DE DOENçAS ASSOCIADAS COM UM AUMENTO DE RECEPTORES AT-1 OU AT-2"<D>. A invenção refere-se ao uso de um antagonista receptor AT~ 1~ ou um modulador receptor AT~ 2~ respectivamente, ou um sal farmaceuticamente aceitável destes, para a produção de uma preparação farmacêutica para o tratamento de condições ou doenças associadas com o aumento de receptores AT~ 1~ na área subepitelial ou aumento de receptores AT~ 2~ nos epitélios.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98811258A EP1013273A1 (en) | 1998-12-23 | 1998-12-23 | Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors |
EP98811257 | 1998-12-23 | ||
PCT/EP1999/010330 WO2000038676A1 (en) | 1998-12-23 | 1999-12-22 | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9916576A true BR9916576A (pt) | 2001-10-02 |
Family
ID=26152118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9916576-7A BR9916576A (pt) | 1998-12-23 | 1999-12-22 | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 |
Country Status (26)
Country | Link |
---|---|
EP (3) | EP2298298A3 (pt) |
JP (2) | JP2002533390A (pt) |
KR (1) | KR100646716B1 (pt) |
CN (2) | CN1304000C (pt) |
AT (2) | ATE354364T1 (pt) |
AU (4) | AU3043000A (pt) |
BR (1) | BR9916576A (pt) |
CA (2) | CA2351357A1 (pt) |
CY (2) | CY1106581T1 (pt) |
CZ (2) | CZ293257B6 (pt) |
DE (1) | DE69935249T2 (pt) |
DK (2) | DK1140071T3 (pt) |
ES (2) | ES2373556T3 (pt) |
HK (1) | HK1038888B (pt) |
HU (1) | HUP0104780A3 (pt) |
ID (1) | ID29856A (pt) |
IL (5) | IL143233A0 (pt) |
NO (2) | NO328775B1 (pt) |
NZ (3) | NZ587909A (pt) |
PL (1) | PL199100B1 (pt) |
PT (2) | PT1140071E (pt) |
RU (3) | RU2271809C2 (pt) |
SI (2) | SI1588706T1 (pt) |
SK (1) | SK9132001A3 (pt) |
TR (7) | TR200805275T2 (pt) |
WO (1) | WO2000038676A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG162605A1 (en) * | 2000-06-22 | 2010-07-29 | Novartis Ag | Pharmaceutical compositions |
JP4972847B2 (ja) * | 2000-10-11 | 2012-07-11 | 住友化学株式会社 | コラーゲン蓄積抑制剤 |
JPWO2002083127A1 (ja) * | 2001-04-09 | 2004-09-30 | 宮田 敏男 | 蛋白修飾物生成抑制組成物 |
DK1395566T3 (da) | 2001-05-31 | 2008-01-07 | Vicore Pharma Ab | Tricycliske forbindelser, der er nyttige som angiotensin Il-agonister |
US7812044B2 (en) | 2001-11-13 | 2010-10-12 | Takeda Pharmaceutical Company Limited | Anticancer agents |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
SK50472005A3 (sk) * | 2003-11-03 | 2005-09-08 | Zentiva, A. S. | Tableta s obsahom valsartanu vyrobená priamym tabletovaním |
RS52607B (en) | 2004-12-24 | 2013-04-30 | Krka Tovarna Zdravil D.D., Novo Mesto | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN |
EP1830869B1 (en) * | 2004-12-24 | 2013-05-22 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
ES2246742B1 (es) * | 2005-09-06 | 2007-02-01 | Prous Institute For Biomedical Research S.A. | Uso de un derivado de imidazol. |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
US20110027358A1 (en) * | 2007-03-29 | 2011-02-03 | Rajesh Kshirsagar | Valsartan tablet formulations |
TR200703568A1 (tr) | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
CA2701695A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
PT2295035T (pt) | 2007-11-06 | 2016-08-22 | Novartis Ag | Composições farmacêuticas de dupla acção com base em superestruturas de antagonista/bloqueador de receptores de angiotensina (arb) com inibidor da endopeptidase neutra (nep) |
WO2009092052A2 (en) | 2008-01-18 | 2009-07-23 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating polyps |
GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
WO2010104485A2 (en) | 2009-03-11 | 2010-09-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
EP2536396B1 (en) | 2010-02-16 | 2016-08-10 | KRKA, D.D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
EP2455388A1 (en) | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Novel angiotensin type 2 (AT2) receptor agonists and uses thereof. |
CN102266307B (zh) * | 2011-08-01 | 2012-10-24 | 海南锦瑞制药股份有限公司 | 一种缬沙坦胶囊及其制备方法 |
WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
EA018867B1 (ru) * | 2012-11-01 | 2013-11-29 | Лаборатория Тютор С.А.С.И.Ф.И.А. | Способ получения фармацевтической композиции и продукт способа |
EP4007592A1 (en) | 2019-08-02 | 2022-06-08 | LanthioPep B.V. | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
WO2024026528A1 (en) * | 2022-08-02 | 2024-02-08 | Dimerix Bioscience Pty Ltd | Dosage regimen for the treatment of copd |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3146168A (en) | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
ATE108996T1 (de) * | 1988-02-25 | 1994-08-15 | Brocades Pharma Bv | Verfahren zur herstellung eines pharmazeutischen granulats. |
DE10075018I2 (de) | 1989-06-14 | 2001-08-09 | Smithkline Beecham Corp | Imidazoalkensäure. |
IE70593B1 (en) | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
PT97078B (pt) | 1990-03-20 | 1997-07-31 | Sanofi Sa | Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
IL99246A0 (en) | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
WO1992005784A1 (en) * | 1990-10-02 | 1992-04-16 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
DE4038335A1 (de) * | 1990-12-01 | 1992-06-04 | Boehringer Mannheim Gmbh | Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel |
SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
US5196537A (en) | 1991-03-21 | 1993-03-23 | G. D. Searle & Co. | 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders |
GB9110636D0 (en) | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DE4132632A1 (de) * | 1991-10-01 | 1993-04-08 | Bayer Ag | Substituierte imidazolyl-propensaeurederivate |
DE4309968A1 (de) * | 1993-03-26 | 1994-09-29 | Bayer Ag | Phenylglycinamide von heterocyclisch substituierten Phenylessigsäurederivaten |
JPH07505646A (ja) | 1992-04-13 | 1995-06-22 | ゼネカ・リミテッド | 神経伝達速度の減損を伴う障害,特に糖尿病性ニューロパシーに対するアンギオテンシンiiアンタゴニスト |
JPH08505374A (ja) | 1992-12-11 | 1996-06-11 | チバ−ガイギー アクチェンゲゼルシャフト | ベンズアゼピノン誘導体 |
NZ258888A (en) * | 1992-12-11 | 1997-02-24 | Ciba Geigy Ag | Benzazepin-2-one derivatives; preparations and pharmaceutical compositions |
DE4309963A1 (de) * | 1993-03-26 | 1994-09-29 | Hubert Kamperschroer | Faß zum Austragen von Gülle |
FR2716882B1 (fr) * | 1994-03-04 | 1996-04-05 | Roussel Uclaf | Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques. |
DE4408497A1 (de) * | 1994-03-14 | 1995-09-21 | Thomae Gmbh Dr K | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU1850695A (en) * | 1994-03-17 | 1995-10-03 | Novartis Ag | Treatment of diabetic nephropathy with valsartan |
DE4432860A1 (de) * | 1994-09-15 | 1996-03-21 | Merck Patent Gmbh | Imidazopyridine |
EP0853477B1 (en) | 1995-10-06 | 2002-10-09 | Novartis AG | At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
WO1997031624A1 (en) | 1996-02-27 | 1997-09-04 | Purdue Research Foundation | Liposomal delivery system |
WO1997031634A1 (en) * | 1996-02-29 | 1997-09-04 | Novartis Ag | At1 receptor antagonist for the stimulation of apoptosis |
GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
DE19628617A1 (de) * | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
CN1234357C (zh) | 1998-07-10 | 2006-01-04 | 诺瓦提斯公司 | 缬沙坦和钙通道阻断剂的抗超敏组合 |
PT1146872E (pt) | 1999-01-26 | 2006-10-31 | Novartis Ag | Utilizacao de antagonistas do receptor de angiotensina ii para tratamento de enfarte agudo do miocardio. |
SG162605A1 (en) * | 2000-06-22 | 2010-07-29 | Novartis Ag | Pharmaceutical compositions |
WO2005039637A2 (en) | 2003-10-17 | 2005-05-06 | Novartis Ag | Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker |
JP2009018990A (ja) | 2005-10-25 | 2009-01-29 | Univ Kurume | C型肝炎ウイルス由来ペプチド |
-
1999
- 1999-12-22 CA CA002351357A patent/CA2351357A1/en not_active Abandoned
- 1999-12-22 HU HU0104780A patent/HUP0104780A3/hu unknown
- 1999-12-22 CN CNB998150452A patent/CN1304000C/zh not_active Expired - Fee Related
- 1999-12-22 CA CA2622805A patent/CA2622805C/en not_active Expired - Fee Related
- 1999-12-22 SI SI9931064T patent/SI1588706T1/sl unknown
- 1999-12-22 TR TR2008/05275T patent/TR200805275T2/xx unknown
- 1999-12-22 AT AT99964665T patent/ATE354364T1/de not_active IP Right Cessation
- 1999-12-22 PT PT99964665T patent/PT1140071E/pt unknown
- 1999-12-22 SK SK913-2001A patent/SK9132001A3/sk unknown
- 1999-12-22 AU AU30430/00A patent/AU3043000A/en not_active Abandoned
- 1999-12-22 TR TR2001/01784T patent/TR200101784T2/xx unknown
- 1999-12-22 AT AT05013209T patent/ATE524176T1/de active
- 1999-12-22 PL PL349424A patent/PL199100B1/pl not_active IP Right Cessation
- 1999-12-22 TR TR2006/05472T patent/TR200605472T1/xx unknown
- 1999-12-22 TR TR2008/05740T patent/TR200805740T1/xx unknown
- 1999-12-22 DE DE69935249T patent/DE69935249T2/de not_active Revoked
- 1999-12-22 ID IDW00200101299Q patent/ID29856A/id unknown
- 1999-12-22 NZ NZ587909A patent/NZ587909A/en not_active IP Right Cessation
- 1999-12-22 TR TR2008/05741T patent/TR200805741T2/xx unknown
- 1999-12-22 ES ES05013209T patent/ES2373556T3/es not_active Expired - Lifetime
- 1999-12-22 PT PT05013209T patent/PT1588706E/pt unknown
- 1999-12-22 BR BR9916576-7A patent/BR9916576A/pt not_active IP Right Cessation
- 1999-12-22 WO PCT/EP1999/010330 patent/WO2000038676A1/en active IP Right Grant
- 1999-12-22 TR TR2002/00764T patent/TR200200764T2/xx unknown
- 1999-12-22 DK DK99964665T patent/DK1140071T3/da active
- 1999-12-22 JP JP2000590630A patent/JP2002533390A/ja not_active Withdrawn
- 1999-12-22 KR KR1020017007996A patent/KR100646716B1/ko not_active IP Right Cessation
- 1999-12-22 EP EP10010334A patent/EP2298298A3/en not_active Withdrawn
- 1999-12-22 ES ES99964665T patent/ES2281978T3/es not_active Expired - Lifetime
- 1999-12-22 CZ CZ20012306A patent/CZ293257B6/cs not_active IP Right Cessation
- 1999-12-22 TR TR2006/05471T patent/TR200605471T2/xx unknown
- 1999-12-22 RU RU2001119990/15A patent/RU2271809C2/ru not_active IP Right Cessation
- 1999-12-22 IL IL14323399A patent/IL143233A0/xx not_active IP Right Cessation
- 1999-12-22 EP EP05013209A patent/EP1588706B1/en not_active Revoked
- 1999-12-22 SI SI9930963T patent/SI1140071T1/sl unknown
- 1999-12-22 NZ NZ553010A patent/NZ553010A/en not_active IP Right Cessation
- 1999-12-22 DK DK05013209.1T patent/DK1588706T3/da active
- 1999-12-22 NZ NZ511938A patent/NZ511938A/xx not_active IP Right Cessation
- 1999-12-22 CN CNA200410087973XA patent/CN1636561A/zh active Pending
- 1999-12-22 EP EP99964665A patent/EP1140071B1/en not_active Revoked
- 1999-12-22 CZ CZ20032559A patent/CZ297795B6/cs not_active IP Right Cessation
-
2001
- 2001-05-17 IL IL143233A patent/IL143233A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013143A patent/NO328775B1/no not_active IP Right Cessation
-
2002
- 2002-01-28 HK HK02100661.6A patent/HK1038888B/zh not_active IP Right Cessation
-
2003
- 2003-12-02 AU AU2003266433A patent/AU2003266433B2/en not_active Ceased
-
2005
- 2005-08-01 RU RU2005124363/15A patent/RU2361575C2/ru not_active IP Right Cessation
-
2006
- 2006-07-18 AU AU2006203077A patent/AU2006203077B2/en not_active Expired
- 2006-11-02 IL IL179017A patent/IL179017A0/en unknown
- 2006-11-02 IL IL179016A patent/IL179016A0/en unknown
- 2006-11-02 IL IL179015A patent/IL179015A0/en unknown
-
2007
- 2007-05-10 CY CY20071100642T patent/CY1106581T1/el unknown
-
2008
- 2008-11-05 RU RU2008143545/15A patent/RU2008143545A/ru unknown
-
2009
- 2009-09-24 AU AU2009220022A patent/AU2009220022B2/en not_active Expired
-
2010
- 2010-01-12 NO NO20100041A patent/NO20100041L/no not_active Application Discontinuation
- 2010-01-18 JP JP2010008140A patent/JP5254258B2/ja not_active Expired - Lifetime
-
2011
- 2011-12-06 CY CY20111101213T patent/CY1112395T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9916576A (pt) | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 | |
BR0213358A (pt) | Uso de flibanserina | |
MY117251A (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
BR9913457A (pt) | Neuroproteção | |
BR0314488A (pt) | Composto, composição farmacêutica e métodos de tratamento | |
BR9909138A (pt) | Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda | |
BR9912588A (pt) | Prevenção de recorrência de enxaqueca | |
BR9913337A (pt) | Derivados tan-1057 | |
IL206566A0 (en) | Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide | |
BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
BR0214798A (pt) | Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial | |
BR0010092A (pt) | Composto, preparação farmacêutica para a administração oral ou parenteral, uso de um composto, e, uso da preparação farmacêutica | |
BR0011845A (pt) | Complexo farmacêutico | |
WO1999049892A3 (fr) | Utilisation de conjugues p40 actifs par voie nasale | |
IL154777A0 (en) | Il-6 receptor/il-6 chimera in huntington's disease | |
BR0104005A (pt) | Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2 | |
AU8553898A (en) | Use of 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions to treat diseases connected with the endogenous opioid system | |
BR9915009A (pt) | Composto, composição farmacêutica, método de estimular a liberação do hormÈnio do crescimento da pituitária de um mamìfero, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
BR0013921A (pt) | Composições farmacêuticas para tratamento de psorìase | |
BR9609937A (pt) | Composição contendo ácido mefenâmico em associação com codeìna | |
ITMI20011634A1 (it) | Uso dei derivati dell'acido idrossamico per la preparazione di medicamenti anti-tumorali | |
ECSP003597A (es) | Derivados de pirrolidin - 2, 3, 4- trion -3- oxima sustituida procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 16A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |